(Q40933391)

English

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

scientific article published on 23 October 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

phase III clinical trial

0 references

0 references

Robert Weatherholtz

3

object named as

Robert Weatherholtz

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

object named as

Hasan S Jafri

4

0 references

object named as

Katherine L O'Brien

1

0 references

Mathuram Santosham

14

object named as

Mathuram Santosham

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

13

object named as

Ruth A Karron

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Lawrence H. Moulton

11

object named as

Lawrence H Moulton

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

2

object named as

Aruna Chandran

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

author name string

M Pamela Griffin

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Terramika Bellamy

6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Eugene V Millar

7

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Kathryn M Jensen

8

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Brian S Harris

9

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Raymond Reid

10

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Genevieve A Losonsky

12

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Respiratory Syncytial Virus (RSV) Prevention study group

15

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

publication date

23 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

1398-1408

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology and prevention of respiratory syncytial virus infections among infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus infection in Navajo and White Mountain Apache children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900247-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(15)00247-9

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40933391&oldid=1910874604"